康希諾(688185.SH):4名股東1月11日合計減持H股315萬股
格隆匯1月12日丨康希諾(688185.SH)公佈,公司於2022年1月12日收到股東LAV Spring、LAV Bio、Lilly Asia及LAV Amber出具的《關於股份減持情況的吿知函》,4名股東於2022年1月11日合計減持H股315萬股,佔公司總股本約1.27%。
於2022年1月10日香港聯合交易所有限公司交易時段後,禮來亞洲基金(Lilly Asia Ventures)下屬相關投資實體作為賣方分別與配售代理訂立配售協議,委託配售代理銷售其所持的公司H股股份共計315萬股,佔本公司總股本約1.27%,於2022年1月11日於香港聯合交易所有限公司與買受方進行場內交易,並將於2022年1月13日完成該等股份的交割。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.